The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APYX | +123.72% | -49.27% | -12.68% | +6% |
| S&P | +16.49% | +84.25% | +12.99% | +1,557% |
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
The share price was cut nearly in half after the company withdrew its FDA application for a new medical device
Shares nose-dive after the company finds itself on the receiving end of a bearish report.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.88M | 12.1% |
| Gross Profit | $5.11M | 48.2% |
| Gross Margin | 39.65% | 9.7% |
| Market Cap | $80.93M | 88.4% |
| Market Cap / Employee | $367.88K | 0.0% |
| Employees | 220 | -12.7% |
| Net Income | -$1,955.00K | 58.6% |
| EBITDA | -$668.00K | 80.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.14M | -10.3% |
| Accounts Receivable | $13.00M | -0.3% |
| Inventory | 9.1 | 1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $38.80M | 0.8% |
| Short Term Debt | $414.00K | 18.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.63% | 22.7% |
| Return On Invested Capital | -36.22% | -3.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,055.00K | 11.7% |
| Operating Free Cash Flow | -$3,536.00K | 20.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.96 | 3.64 | 8.09 | 11.15 | 186.60% |
| Price to Sales | 1.26 | 1.18 | 1.97 | 1.82 | 105.70% |
| Price to Tangible Book Value | 4.96 | 3.64 | 8.09 | 11.15 | 186.60% |
| Enterprise Value to EBITDA | -23.24 | -21.91 | -41.61 | -151.96 | 883.33% |
| Return on Equity | -114.7% | -130.3% | -156.9% | -172.2% | 34.36% |
| Total Debt | $38.76M | $38.92M | $39.08M | $39.21M | 0.94% |
No podcast episodes available.
APYX earnings call for the period ending March 31, 2020.
APYX earnings call for the period ending December 31, 2019.
APYX earnings call for the period ending September 30, 2019.
APYX earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
